Hologic has appointed José “Joe” Almeida as CEO following the completion of its acquisition by Blackstone and TPG. Almeida succeeds Stephen MacMillan, who retired after more than 12 years leading the women’s health company. The $18.3 billion take-private deal gives Hologic new ownership as it weighs product innovation, acquisitions, and longer-term growth outside the pressures of the public market.
Almeida previously served as CEO of Baxter, where he led a strategic repositioning that included the $10.5 billion acquisition of Hillrom and the separation of several business units. Hologic cited his experience in operational improvement, portfolio strategy, and medical product innovation as key factors in the appointment. Before Baxter, Almeida led Covidien until its acquisition by Medtronic in 2015.
The appointment places Almeida at the center of Hologic’s first chapter as a private company. Blackstone and TPG completed the acquisition in April, and Hologic’s common stock has ceased trading and will be delisted from Nasdaq. For Almeida, the role brings a mandate to guide a women’s health business with established diagnostics, imaging, and surgical platforms through its next phase of private-equity-backed growth.